Nawang, Naseha .
HRN: 19-49-27 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/04/2023
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
10/04/2023
10/10/2023
IVT
400mg
Q6
Pcap C
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes